[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646782":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: GLP-1 RAs combined with healthy lifestyle education","EXPERIMENTAL","Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.) was administered at an initial dose of 0.06 mg per injection, three times daily, via subcutaneous injection 5 minutes before meals. After establishing tolerance, the dose was increased weekly by 0.04 mg per injection, reaching 0.2 mg per injection after four weeks, administered three times daily for a total of 12 weeks.Assisted reproductive treatment was initiated upon completion of the 12-week intervention.",[13],"Drug: GLP-1 receptor agonist",{"label":15,"type":16,"description":17,"interventionNames":18},"metformin and healthy lifestyle education","ACTIVE_COMPARATOR","Metformin hydrochloride (Glucophage®, National Medicine Standard No. H20023370, Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.) was administered at a dose of 0.5 g twice daily for 12 weeks, taken with meals. Assisted reproductive treatment was initiated upon completion of the 12-week intervention.",[19],"Drug: Metformin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","GLP-1 receptor agonist","12 weeks treatment",[9],null,{"type":22,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"Metformin",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Shuo Huang","CONTACT","+861082266699","homelyleaf@aliyun.com",[37],{"facility":5,"status":26,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing","Beijing Municipality","100191","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":34,"phoneExt":26,"email":52},"Liang Liang","lliangftll@163.com",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Huangshuo","Associate Professor","100646782","effects-of-glp-1ras-on-fertility-outcomes-in-obese-women-with-pcos-100646782",false,"NCT07687667","Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS","Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Women with a wish to conceive;\n* Women with PCOS (Rotterdam criteria);\n* 28 kg\u002Fm2≤BMI\\\u003C35kg\u002Fm2;\n* Age: 18-40 years old\n\nExclusion Criteria:\n\n* Women with diseases unsuitable for pregnancy or any other contraindications to infertility treatment Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (\\>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine abnormalities that may affect assisted reproductive outcomes, untreated hydrosalpinx Male azoospermia, severe oligozoospermia and asthenospermia, or patients receiving donor sperm treatment Chromosomal abnormalities, patients planning preimplantation genetic testing (PGT) or donor oocyte treatment History of recurrent miscarriag Allergic to or contraindicated for GLP-1 class medications.","FEMALE","18 Years","40 Years",{"count":68,"type":69},406,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this clinical trial is to examine whether GLP1-RA and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.",[75,76,77],"Polycystic Ovary Syndrome (PCOS)","Obesity","Infertility, Female","NOT_YET_RECRUITING","2026-07-01",{"date":81,"type":82},"2026-07-07","ACTUAL",{"date":84,"type":69},"2026-07",{"date":86,"type":69},"2029-12",{"name":5,"class":6},1]